Core Insights - The company reported a revenue of 375 million yuan for the first half of 2025, impacted by a slowdown in investment and market demand in the domestic pharmaceutical industry, leading to increased competition and reduced sales order prices [1] - New order value reached 532 million yuan, a year-on-year increase of 7.39%, while the backlog of orders grew to 1.112 billion yuan, up 14.29% from the end of 2024 [1] - The company maintained a strong focus on R&D, with R&D expenditure as a percentage of revenue rising from 3.67% to 5.94%, reflecting a commitment to technological innovation and long-term growth potential [1] Business Performance - All business segments performed well, with the core IND and NDA new project numbers increasing by 6.86% year-on-year, showcasing the company's strong market expansion capabilities [1] - The company secured one new authorized invention patent during the reporting period, bringing the total number of authorized patents to 69 by the end of the reporting period [1] International Expansion - The company has established itself as a leading CRO in China, being one of the first to obtain GLP certifications from NMPA, OECD, and FDA, aligning with international standards [2] - Significant growth in international business new orders was noted, enhancing the company's recognition and influence in the global market [2] - The company has assisted in over 200 innovative drug research services, including several groundbreaking therapies and products, demonstrating its capability in both domestic and international markets [2] Capacity Development - The company successfully launched its strategic project in Nantong, covering an area of 24,000 square meters and planning 130 international standard animal housing units, which will enhance its capabilities in innovative molecules and advanced therapies [3]
益诺思2025年半年报：新签订单增长良好，产能扩增稳步推进